Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xencor Inc. (XNCR)
:XNCR
Holding XNCR?
Track your performance easily
XNCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.31 - $27.24
Previous CloseN/A
Volume126.93K
Average Volume (3M)723.75K
Market Cap
$1.34B
Enterprise Value$828.17M
Total Cash (Recent Filing)$130.14M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Mar 03, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding69,982,030
10 Day Avg. Volume571,870
30 Day Avg. Volume723,745
Standard Deviation0.11
R-Squared0.11
Alpha-0.00881
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.48
Price to Cash Flow (P/CF)-13.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue9.73
Enterprise Value/Gross Profit4.92
Enterprise Value/Ebitda-5.31
Forecast
1Y Price Target
$31.56Price Target Upside57.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Xencor News
PremiumCompany Announcements
Xencor Highlights Progress in Drug Development Pipeline
PremiumCompany Announcements
Xencor Reports Q3 2024 Earnings and Program Updates
PremiumPre-Earnings
Is XNCR a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial Position And PipelineXencor ended 3Q:24 with cash of $754 million to fund operations into 2028.
Innovative PlatformsThe company's Xtend platform, which can increase half-life of mAbs by 3x, is validated by approved drugs such as Ultomiris.
Partnerships And Drug ApprovalThe company's antibody platform has led to several partnerships and 3 approved drugs, showcasing its effectiveness and credibility.
Bears Say
Clinical TrialsXencor's antibody candidates may fail in the clinic.
PartnershipsThe company's partnerships may falter.
Safety ConcernsThere have been two dose-limiting toxicity events reported in the XmAb808 study, including an infusion-related reaction and an immune-related hepatitis.
---
Ownership Overview
1.29% Insiders
34.43% Mutual Funds
0.20% Other Institutional Investors
37.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XNCR FAQ
What was Xencor Inc.’s price range in the past 12 months?
Xencor Inc. lowest stock price was $15.31 and its highest was $27.24 in the past 12 months.
What is Xencor Inc.’s market cap?
Xencor Inc.’s market cap is $1.34B.
When is Xencor Inc.’s upcoming earnings report date?
Xencor Inc.’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were Xencor Inc.’s earnings last quarter?
Xencor Inc. released its earnings results on Nov 07, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.981 by $0.271.
Is Xencor Inc. overvalued?
According to Wall Street analysts Xencor Inc.’s price is currently Undervalued.
Does Xencor Inc. pay dividends?
Xencor Inc. does not currently pay dividends.
What is Xencor Inc.’s EPS estimate?
Xencor Inc.’s EPS estimate is -0.78.
How many shares outstanding does Xencor Inc. have?
Xencor Inc. has 69,982,030 shares outstanding.
What happened to Xencor Inc.’s price movement after its last earnings report?
Xencor Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.981. Following the earnings report the stock price went up 2.205%.
Which hedge fund is a major shareholder of Xencor Inc.?
Currently, no hedge funds are holding shares in XNCR
---
Xencor Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.56 (57.41% Upside)
$31.56 (57.41% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.76%
12-Months-Change
Fundamentals
Return on Equity
-28.47%
Trailing 12-Months
Asset Growth
26.36%
Trailing 12-Months
Company Description
Xencor Inc.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
---
XNCR Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant pipeline progress and a strong financial position. However, safety concerns with vudalimab and a strategic pause on XmAb564 development were noted.Read More>---
XNCR Stock 12 Month Forecast
Average Price Target
$31.56
▲(57.41% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Fate Therapeutics
―
Adaptive Biotechnologies
―
Zymeworks
―
Karyopharm Therapeutics
―
Curis
―
Best Analysts Covering XNCR
1 Year
1 Year Success Rate
16/39 ratings generated profit
1 Year Average Return
-7.52%
assigned a buy rating 12 months ago
Copying Mara Goldstein's trades and holding each position for 1 Year would result in 41.03% of your transactions generating a profit, with an average return of -7.52% per trade.
---